Accelerated development of appropriate patient therapies: a sustainable, multi-stakeholder approach from research to treatment-outcomes


Start Date
End Date
IMI2 - Call 4
Grant agreement number

IMI Funding
1 130 000
EFPIA in kind
2 271 631
662 515
Total Cost4 064 146


Europe faces many challenges in bringing new medicines to patients in an efficient and timely manner. The reasons for this include the high attrition rates in medicine development, a regulatory environment lagging behind rapidly evolving science, and research and development (R&D) and price/reimbursement models that are no longer financially viable.

‘Medicines adaptive pathways to patients’ (MAPPs) refers to a concept that seeks to provide patients with timely access to beneficial medicines, starting from a small group of well-identified patients (often those with little or no alternative treatments). As evidence accumulates on the benefits and risks of a medicine, access may be extended to other groups of patients. MAPPs relate to a flexible pathway covering the entire life cycle of a medicine, from development, through licensing, to patient access (pricing/reimbursement and healthcare delivery).

ADAPT-SMART is a coordination and support action that brings together representatives from key European stakeholder groups - regulatory agencies, health technology assessment (HTA) bodies, companies, payers, patients and health care professionals. Its goal is to create a platform where the conditions and feasibility of MAPPs implementation within the EU regulatory/legal context can be discussed openly and also ensure that MAPPs-related work in IMI is well coordinated.

Achievements & News

Sign up for the ADAPT SMART final conference
February 2018

The IMI ADAPT SMART Closing Meeting ‘Medicines Development in the Adaptive Era’ will take place in Budapest, Hungary on 21-22 March. During the event, the final results of the project will be presented and placed into the context of public health and sustainable pharmaceutical innovation in Europe and beyond. ### As part of the programme, MIT’s NEWSDIGS (‘NEW Drug Development ParadIGmS’) programme will host an interactive session to apply the learnings from ADAPT SMART to a case study. All audience members will have the opportunity to contribute to the case study discussions. The meeting will close with a look into the future of adaptive pathways beyond ADAPT SMART. Registration is upon invitation only and seating is limited – to request an invitation, follow the link at the bottom of the event web page.

ADAPT SMART issues discussion paper on engagement criteria for MAPPs
January 2017

The ADAPT SMART project has issued a discussion paper on engagement criteria for MAPPs (medicines adaptive pathways to patients) to aid in debates on how and when a MAPPs approach should be used and for which medicines and diseases/conditions. The paper proposes the following set of six questions to consider when selecting individual products for a MAPPs pathway.###

  1. Can we define a target population with a high unmet need? Does the product hold sufficient promise to address the unmet need?
  2. Can a prospective iterative post- (initial) marketing authorisation development plan be proposed, developed, implemented and agreed?
  3. Are there workable tools to ensure appropriate product utilisation?
  4. Are there workable ‘strategies’ for payers in case the product under-performs?
  5. Is there sufficient commitment and resources from relevant stakeholders to ensure successful interactions?
  6. Which critical aspects for pharmaceutical development would need to be considered?

The questions are designed to initially trigger discussions at the company level (i.e. the medicine developer) and subsequently during discussions between the company and other stakeholders. These questions were designed on the basis of input gathered from a wide range of stakeholders, including regulators, payers, HTA bodies, prescribers, patients and companies. The paper is intended to inform and drive future discussions on MAPPs, both within the ADAPT SMART consortium and in the wider scientific and healthcare communities.

ADAPT SMART makes the case for early access
July 2016

The question of whether, and how, patients with serious diseases should be allowed early access to promising new treatments is hotly debated. Now IMI’s ADAPT SMART project has put together a simple guide to early access that begins with the story of two fictional patients.### Jane has advanced cancer and has at best a year or two to live. John has a family history of cancer, but is currently fit and healthy. If both are told about an experimental new treatment that looks promising but needs more testing, their responses will likely be very different. John hopes that if he is diagnosed with cancer in several years’ time, the treatment will be thoroughly tested. Jane cannot wait so long, and is willing to accept the uncertainties that come with the experimental treatment. However, as the project notes, ‘healthcare decision-makers have an obligation to cater to the needs of both Jane and John’. The project goes on to explain how Medicines Adaptive Pathways to Patients (MAPPs) seek to foster access to beneficial treatments for the right patient groups at the earliest appropriate time and in a sustainable fashion. The key features of MAPPs are:

  • focuses on the promise to address a high unmet need;
  • provides timely access for the target population in need;
  • uses an iterative development and assessment plan with evidence generation over the entire life-span of the drug;
  • harnesses real world data to inform follow-on licensing and reimbursement decisions and to manage risks;
  • provides for the adjustment of the treatment-eligible population;
  • manages utilisation;
  • facilitates the collaboration of all stakeholders (pharmaceutical companies, patients, regulators, HTAs, payers, health care providers);
  • ensures the sustainability of the innovation and healthcare systems.

GetReal and ADAPT-SMART launch glossaries
June 2016

Information on drug development is often filled with jargon. Now IMI’s GetReal and ADAPT SMART projects  have released new/updated glossaries to facilitate discussions in their respective subject areas.###

GetReal is investigating how to best incorporate ‘real world evidence’ into drug development. Its updated glossary, which was the subject of a consultation, also includes a more detailed discussion on questions such as the difference between ‘efficacy’ and ‘effectiveness’.

ADAPT SMART was set up (among other things) to coordinate IMI activities in the area of MAPPs (medicines adaptive pathways to patients). Many of the items in its glossary are drawn from the GetReal glossary. The project welcomes feedback on the glossary.

Participants Show participants on map

EFPIA companies
  • AbbVie Ltd, Maidenhead, United Kingdom
  • Amgen NV, Brussels, Belgium
  • Astellas Pharma Europe LTD, Chertsey, United Kingdom
  • AstraZeneca AB, Södertälje, Sweden
  • Bayer AG, Berlin, Germany
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany
  • Eli Lilly and Company Ltd, Basingstoke, United Kingdom
  • European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD, Brentford, Middlesex, United Kingdom
  • H. Lundbeck A/S, Valby, Denmark
  • Institut De Recherches Internationales Servier, Suresnes, France
  • Ipsen Innovation S.A.S., Les Ulis, France
  • Janssen Pharmaceutica NV, Beerse, Belgium
  • Lysogene, Neuilly sur Seine, France
  • Merck KGaA, Darmstadt, Germany
  • Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Sanofi-Aventis Research and Development, Chilly Mazarin, France
  • Shire International GmbH , Zug, Switzerland
  • UCB Biopharma SPRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Agenzia Italiana del Farmaco, Rome, Italy
  • Haute Autorité de Santé, Saint-Denis la Plaine , France
  • Massachusetts Institute of Technology, Cambridge, United States
  • National Institute for Health and Care Excellence, Manchester, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Zorginstituut Nederland, Diemen, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Stichting Lygature, Utrecht, Netherlands
Patient organisations
  • European Organisation for Rare Diseases, Paris, France
  • Forum Europeen Des Patients - European Patients' Forum, Brussels, Belgium
Non EFPIA companies
  • European Medicines Agency, Canary Wharf, London, United Kingdom


Project leader
Hans-Georg Eichler
European Medicines Agency
Project coordinator
Andre Broekmans
Stichting Lygature
31 (0)6 10139041
Project management
Pieter Stolk
TI Pharma